Exosome News and Research

RSS

Drug delivery breakthrough for Alzheimer’s disease

Till date all attempts to get drugs into the brain were countered by the blood-brain barrier - the natural defense against potentially harmful chemicals floating around the body. However this new finding from a team from University of Oxford shows that now scientists have successfully switched off a gene implicated in Alzheimer’s disease in the brains of mice by exploiting tiny particles naturally released by cells, called exosomes.

21 Mar 2011

Presence of jumping genes, amplified oncogenes may be key to tumor progression: Researchers

The Massachusetts General Hospital research team that first discovered tumor-associated RNA in tiny membrane-enclosed sacs released into the bloodstream by cancer cells has now found that these microvesicles also contain segments of tumor DNA, including retrotransposons - also called "jumping genes" - that copy and insert themselves into other areas of the genome.

10 Feb 2011

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has demonstrated the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.

20 Dec 2010

Research reveals EBV virus infected cell manipulates cancer-producing cells

A new discovery by UNC scientists describes how cells infected by the Epstein-Barr virus (EBV) produce small vesicles or sacs called exosomes, changing their cellular "cargo" of proteins and RNA. This altered exosome enters cells and can change the growth of recipient cells from benign to cancer-producing.

9 Nov 2010

Aethlon Medical engages Fabiani & Company to assist in establishment of federal partnerships

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has engaged Fabiani & Company to assist in the establishment of federal partnerships that advance biodefense, cancer, and chronic infectious disease applications of the Aethlon Hemopurifier®.

30 Sep 2010

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has reestablished efforts to advance the Aethlon Hemopurifier within U.S. Government programs that support the development and purchase of treatment countermeasures against bioterror threats.

21 Sep 2010

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its researchers have demonstrated the ability of the Aethlon Hemopurifier® to capture immunosuppressive exosomes derived from individuals with metastatic melanoma.

9 Sep 2010

Forbion Capital Partners announces final closing of FCF I, FCF II fund

Forbion Capital Partners, a leading investment firm dedicated to the life science sector, today announces the final closings of both FCF I Co-Invest Fund and of FCF II, raising a total of more than €190m ($240m). Forbion's €54m Co-Invest Fund aims to invest alongside FCF I in a select number of late-stage FCF I portfolio companies.

3 Sep 2010

Aethlon Medical receives approval for Chronic HCV Infection treatment

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Medanta Independent Ethics Committee (MIEC) at Medanta, The Medicity Institute (Medicity) has approved a treatment program entitled "Use of the Aethlon Hemopurifier in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy."

26 Aug 2010

Aethlon Medical files provisional patent on behalf of ESI for exosome detection assay

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has filed a provisional patent on behalf of its wholly owned subsidiary Exosome Sciences, Inc. (ESI), relating to the development of an assay that will allow researchers to detect exosomes in blood and other fluids.

8 Jul 2010

New research suggests tumor-secreted exosomes inhibit immune response, enhance tumor metastasis

Current research suggests that tumor-secreted exosomes inhibit the immune response, enhancing tumor metastasis. The related report by Liu et al, "Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells," appears in the May 2010 issue of The American Journal of Pathology.

3 May 2010

Exosome News and Research

Drug delivery breakthrough for Alzheimer’s disease

Presence of jumping genes, amplified oncogenes may be key to tumor progression: Researchers

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

Research reveals EBV virus infected cell manipulates cancer-producing cells

Aethlon Medical engages Fabiani & Company to assist in establishment of federal partnerships

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Forbion Capital Partners announces final closing of FCF I, FCF II fund

Aethlon Medical receives approval for Chronic HCV Infection treatment

Aethlon Medical files provisional patent on behalf of ESI for exosome detection assay

New research suggests tumor-secreted exosomes inhibit immune response, enhance tumor metastasis

Aethlon Medical establishes ESI as a wholly owned subsidiary

Fat capsules carry markers for deadly prostate cancer

Blood exosomes shown to contain tumor-specific genetic information for brain cancer

Microvesicles released from glioblastoma cells carry information that may guide treatment

HIV uses pathways to infect cells

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News